Fdc Ltd. (BSE: 531599) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹6,358 Cr, it ranks #756 by market cap among the 6,197 Indian listed companies on FinBizNet, and #21 of 86 in Medicinal Chemicals and Botanical Products. At ₹371.45 (as of 16 Nov 2026), the share price is 16.0% below its 52-week high of ₹442.00 and 18.7% above its 52-week low of ₹312.95. The share price is down 12.7% over one year and up 3.7% over three months.
| Current Price | ₹371.45 |
|---|---|
| Market Cap | ₹6,358 Cr |
| BSE Code | 531599 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 22.6 |
| Return on Equity | 11.81% |
| Return on Assets | 6.37% |
| 52-Week Range | ₹312.95 – ₹442.00 |
| 1-Year Price Change | -12.7% |
| 3-Month Price Change | +3.7% |
| Beta (1Y) | 0.16 |
| Dividend Yield | 2.56% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.fdcindia.com |
| Revenue | ₹572 Cr |
|---|---|
| Net Profit | ₹49 Cr |
| Net Margin | 8.6% |
| EPS (Basic) | ₹3.01 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Fdc Ltd. reported revenue of ₹572 Cr in Q2 FY27, up 21.0% from ₹473 Cr in Q2 FY26 and down 14.3% from ₹668 Cr in Q1 FY27. It posted a net profit of ₹49 Cr for the quarter, against a net profit of ₹28 Cr in Q2 FY26 (up 72.9%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹465 Cr (Q3 FY26) to ₹668 Cr (Q1 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹572 Cr | ₹49 Cr | 8.6% |
| Q1 FY27 | ₹668 Cr | ₹132 Cr | 19.8% |
| Q4 FY26 | ₹585 Cr | ₹103 Cr | 17.7% |
| Q3 FY26 | ₹465 Cr | ₹28 Cr | 6.1% |
| Q2 FY26 | ₹473 Cr | ₹28 Cr | 6.0% |
| Q1 FY26 | ₹648 Cr | ₹121 Cr | 18.7% |
| Q4 FY25 | ₹492 Cr | ₹39 Cr | 7.9% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 69.66% of Fdc Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 51.7% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured ORS powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Vitcofol, Ziglim, Ziglim-M,Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Electral, and Enerzal brands. It also exports its products to app
1. Pharmaceuticals-This segment engages in the pharmaceutical business.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Fdc Ltd. | ₹6,358 Cr | 22.6 | 11.81% | ₹572 Cr | -12.7% |
Listed by market capitalisation. Ratios are shown for context only.
Fdc Ltd. is trading at ₹371.45, with a market capitalisation of ₹6,358 Cr.
Fdc Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Fdc Ltd. has a P/E of 22.6 and a return on equity of 11.81%.
Fdc Ltd. is listed on the BSE under the scrip code 531599.
Fdc Ltd.'s share price is down 12.7% over one year and up 3.7% over three months. Its 52-week range is ₹312.95 to ₹442.00.
In Q2 FY27, Fdc Ltd. reported revenue of ₹572 Cr and net profit of ₹49 Cr, with basic EPS of ₹3.01 (consolidated, parsed from the company's exchange filing).
Fdc Ltd. reported revenue of ₹572 Cr in Q2 FY27, up 21.0% from ₹473 Cr in Q2 FY26 and down 14.3% from ₹668 Cr in Q1 FY27.
Promoters held 69.66% of Fdc Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.